<\/p>\n
Novartis (NVS) had a disappointing Tuesday, Sept. 8. Shares dropped nearly 14% on one of the company’s worst trading days on record.<\/p>\n
The sell-off followed news that a closely watched experimental drug failed its main goal in a late-stage trial. The timing was bad, since the company was already dealing with a trial failure from days earlier.<\/p>\n
Novartis is one of the largest drugmakers in the world. It develops and sells prescription medicines across cancer, heart disease, immunology, and neuroscience.<\/p>\n
Because the company earns most of its money from a handful of popular branded drugs, its business model depends heavily on new drugs reaching the market. So when a major drug trial fails, investors pay attention.<\/p>\n
Why the del-desiran trial failure hit Novartis stock so hard<\/p>\n
The drug in question is del-desiran, an experimental treatment for myotonic dystrophy type 1 (DM1).<\/p>\n
DM1 is a genetic disease that causes progressive muscle stiffness and weakness. There are no approved treatments for it.<\/p>\n
Novartis said its Phase III HARBOR study found no real improvement over patients who got no active treatment. <\/p>\n
The trial’s primary test was on video hand opening time, which tracks how well patients can relax their hand muscles.<\/p>\n
More Pharma Stocks:<\/p>\n
Eli Lilly raises the stakes in $2.88 billion autoimmune buyout<\/p>\n
BofA makes bullish call on newly public biotech stock<\/p>\n
BofA biotech scorecard: two buys and odd one out<\/p>\n
Del-desiran was the main asset from the company’s roughly $12 billion purchase deal with Avidity Biosciences completed in February 2026, according to Novartis. <\/p>\n
The drug had won FDA Fast Track and Breakthrough Therapy status, so hopes for approval ran high.<\/p>\n
Although the primary test failed, Novartis noted some encouraging signs in secondary measures, along with a clean safety record. <\/p>\n
The company plans to review the full data before it decides what comes next.<\/p>\n
Novartis shares fell nearly 14% on Sept. 8, 2026, after a second late-stage drug trial failure in days.<\/p>\n
SOPA Images \/ Getty Images<\/p>\n
A rough stretch for the Novartis pipeline<\/p>\n
This was the second late-stage failure in a matter of days.<\/p>\n
Just before it, Novartis’s heart drug Pelacarsen failed to reduce the risk of major cardiac events in a large trial, Bloomberg reported. <\/p>\n
Analysts had estimated peak sales of roughly $4 billion to $6 billion for that drug, which the company developed with Ionis Pharmaceuticals.<\/p>\n
Related: Morgan Stanley uncovers major Bristol Myers stock signals<\/p>\n
Novartis also recently paused several trials in its experimental CAR-T cancer therapy program after patient deaths. <\/p>\n
Three setbacks in quick succession is a lot for any drugmaker to absorb, and shareholders are recalculating what the pipeline is really worth.<\/p>\n
What Novartis investors should weigh now<\/p>\n
Analysts at Jefferies and Barclays are openly questioning whether Novartis can hit its target of 5% to 6% annual sales growth through 2030, Reuters reported.<\/p>\n
That target looks harder to reach with key patents expiring soon. The company’s top-selling heart drug, Entresto, has already begun to lose exclusivity, and more blockbuster drugs are set to follow.<\/p>\n
Here is what shareholders should keep in mind.<\/p>\n
Key risks and takeaways for Novartis stock<\/p>\n
More deals may be coming. Because internal research has stalled, Novartis may likely buy more biotech firms at high prices to refill its pipeline, which can dilute existing shareholders.<\/p>\n
The premium is fading. Investors treated Novartis as a stable giant, and that reputation is now being repriced lower.<\/p>\n
The dividend is still solid. The stock offers a yield of about 3.4%, which is a cushion for patient holders.<\/p>\n
Volatility is real. Big pharma stocks can swing hard around trial results, so position sizing matters.<\/p>\n
Novartis remains profitable and pays a healthy dividend.<\/p>\n
But the steady reputation that justified its premium price is under pressure, and rebuilding trust in the pipeline will take time and probably more expensive acquisitions.<\/p>\n
For now, cautious investors may want to watch how the company’s management handles the full del-desiran data before they make any big moves.<\/p>\n
Related: Novo Nordisk CEO resets expectations for Wegovy’s explosive growth<\/p>\n
#Novartis #stock #hot #water #key #failure<\/p>\n","protected":false},"excerpt":{"rendered":"
Novartis (NVS) had a disappointing Tuesday, Sept. 8. Shares dropped nearly 14% on one of…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[4640,1300,634,21121,91,1392],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/15779"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15779"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/15779\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}